{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:22Z","timestamp":1793406922709,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50\u201360% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. This retrospective chart review also investigates the impact of CoQ10 and calcium supplementation in patients treated with HHI drugs at a single academic medical center from 2012 to 2022. We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). Secondary objectives included overall survival, BCC-specific survival, time to and reasons for discontinuation, overall response rate, safety and tolerability, use of CoQ10 and calcium supplements, and insurance coverage. Of 55 patients assessable for outcome, 34 (61.8%) had an overall clinical benefit, with 25 (45.4%) having a complete response and 9 (16.3%) a partial response. Stable disease was seen in 14 (25.4%) and 7 (12.7%) progressed. Of the 34 patients who responded to treatment, 9 recurred. Patients who were rechallenged with HHI could respond again. The median overall BCC-specific survival rate at 5 years is 89%. Dose reductions or discontinuations for vismodegib and sonidegib occurred in 59% versus 24% of cases, or 30% versus 9% of cases, respectively. With CoQ10 and calcium supplementation, only 17% required a dose reduction versus 42% without. HHI is highly effective for treating advanced BCC but may require dosing decreases. Sonidegib was better tolerated than vismodegib. CoQ10 and calcium supplementation can effectively prevent muscle spasms.<\/jats:p>","DOI":"10.1371\/journal.pone.0297531","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T18:49:22Z","timestamp":1714502962000},"page":"e0297531","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review"],"prefix":"10.1371","volume":"19","author":[{"given":"Shivani","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Archambeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Jeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Spaccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-8888","authenticated-orcid":true,"given":"Llana","family":"Pootrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"pone.0297531.ref001","volume-title":"StatPearls","author":"B McDaniel","year":"2022"},{"issue":"1","key":"pone.0297531.ref002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2007.09.009","article-title":"The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaining links between skin cancers and solid tumours","volume":"44","author":"WB Grant","year":"2008","journal-title":"Eur J Cancer"},{"key":"pone.0297531.ref003","author":"J Karen","journal-title":"Basal Cell Carcinoma: The Skin Cancer Foundation"},{"issue":"2","key":"pone.0297531.ref004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjd.20700","article-title":"A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).","volume":"186","author":"BJA Verkouteren","year":"2022","journal-title":"Br J Dermatol"},{"key":"pone.0297531.ref005","author":"National Comprehensive Cancer Network (NCCN).","year":"2022","journal-title":"Basal Cell Skin Cancer NCCN Guidelines (version 2.2022"},{"issue":"12","key":"pone.0297531.ref006","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"DD Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0297531.ref007","unstructured":"Erivedge (vismodegib) package insert. Genetech USA, Inc.: San Francisco, CA; 2012."},{"key":"pone.0297531.ref008","unstructured":"Odomzo (sonidegib) package insert. Sun Pharmaceutical Industries, Inc.: Canbury, NJ; 2015."},{"key":"pone.0297531.ref009","unstructured":"Libtayo (cemiplimab-rwlc) package insert. Regeneron Pharmaceuticals, Inc.: Tarrytown, NY; 2021."},{"issue":"11","key":"pone.0297531.ref010","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1073\/pnas.1018217108","article-title":"Sonic hedgehog signaling is decoded by calcium spike activity in the developing spinal cord","volume":"108","author":"YH Belgacem","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5268","key":"pone.0297531.ref011","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"RL Johnson","year":"1996","journal-title":"Science"},{"issue":"6591","key":"pone.0297531.ref012","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/382547a0","article-title":"smoothened encodes a receptor-like serpentine protein required for hedgehog signalling","volume":"382","author":"M van den Heuvel","year":"1996","journal-title":"Nature"},{"issue":"7","key":"pone.0297531.ref013","first-page":"583","article-title":"Hedgehog and its patched-smoothened receptor complex: a novel signalling mechanism at the cell surface","volume":"378","author":"J Alcedo","year":"1997","journal-title":"Biol Chem"},{"issue":"1","key":"pone.0297531.ref014","article-title":"Treatment for mitochondrial disorders.","author":"P Chinnery","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"pone.0297531.ref015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/psm.2012.11.1991","article-title":"Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins.","volume":"40","author":"RE Deichmann","year":"2012","journal-title":"Phys Sportsmed."},{"key":"pone.0297531.ref016","first-page":"202","article-title":"Effect of coenzyme Q10 supplementation on exercise-induced response of inflammatory indicators and blood lactate in male runners","volume":"29","author":"M Armanfar","year":"2015","journal-title":"Med J Islam Repub Iran"},{"key":"pone.0297531.ref017","unstructured":"US Dept. of Health & Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, 2017 [Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf#search=%22CTCAE%22."},{"issue":"2","key":"pone.0297531.ref018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0297531.ref019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies","volume":"111","author":"DR Rivera","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0297531.ref020","volume":"18","author":"W Mohiuddin","year":"2018","journal-title":"Brooke-Spiegler Syndrome. Eplasty"},{"issue":"23","key":"pone.0297531.ref021","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"A Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0297531.ref022","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"N Basset-Seguin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"pone.0297531.ref023","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.1002\/onco.13820","article-title":"Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.","volume":"26","author":"A Kahana","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"pone.0297531.ref024","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaad.2019.12.002","article-title":"Efficacy, rate of tumor response, and safety of a short course (12\u201324 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.","volume":"82","author":"SW Fosko","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0297531.ref025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","article-title":"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma","volume":"73","author":"H Sofen","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"pone.0297531.ref026","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.","volume":"16","author":"MR Migden","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"pone.0297531.ref027","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","article-title":"Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"JY Tang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0297531.ref028","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"A Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"pone.0297531.ref029","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.","volume":"35","author":"N Bertrand","year":"2021","journal-title":"EClinicalMedicine."},{"issue":"1","key":"pone.0297531.ref030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12885-019-5568-6","article-title":"Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"19","author":"A Sekulic","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"pone.0297531.ref031","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"R Dummer","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T18:49:47Z","timestamp":1714502987000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297531"}},"subtitle":[],"editor":[{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0297531","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}